Holen Sie sich die Stockscreener-App
3.88
3.19%
0.12
Handel nachbörslich:
3.89
0.01
+0.26%
Schlusskurs vom Vortag:
$3.76
Offen:
$3.81
24-Stunden-Volumen:
1.13M
Relative Volume:
0.71
Marktkapitalisierung:
$442.39M
Einnahmen:
$884.00K
Nettoeinkommen (Verlust:
$-103.64M
KGV:
-2.7826
EPS:
-1.3944
Netto-Cashflow:
$-95.45M
1W Leistung:
-2.51%
1M Leistung:
-13.20%
6M Leistung:
+74.77%
1J Leistung:
+65.11%
1-Tages-Spanne:
$3.775
$3.995
1-Wochen-Bereich:
$3.52
$4.08
52-Wochen-Spanne:
$1.955
$6.16
Perspective Therapeutics Inc Stock (CATX) Company Profile
Firmenname
Perspective Therapeutics Inc
Sektor
Branche
Telefon
509-375-1202
Adresse
350 Hills Street, Suite 106, Richland
Compare CATX vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
3.88 | 428.71M | 884.00K | -103.64M | -95.45M | -1.3944 |
ABT
Abbott Laboratories
|
82.56 | 146.87B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
282.58 | 109.33B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
74.54 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
53.37 | 80.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
77.17 | 46.04B | 6.30B | 1.07B | 1.09B | 1.8406 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-10-10 | Eingeleitet | BTIG Research | Buy |
| 2025-03-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-11-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-01 | Eingeleitet | Wedbush | Outperform |
| 2024-09-25 | Eingeleitet | Truist | Buy |
| 2024-07-25 | Eingeleitet | BofA Securities | Buy |
| 2024-05-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Perspective Therapeutics Inc Aktie (CATX) Neueste Nachrichten
Perspective Therapeutics (NYSEARCA:CATX) Posts Mixed Q1 2026 Results, EPS Beat and Revenue Miss - ChartMill
Perspective Therapeutics 1Q Loss/Shr 25c >CATX - Moomoo
Is Perspective Therapeutics (CATX) Attractively Valued After Q1 - GuruFocus
Perspective Therapeutics: Q1 Earnings Snapshot - KTVB
Perspective Therapeutics Highlights Q1 Progress and Strengthened Finances - TipRanks
Perspective Therapeutics Q1 net loss widens as grant revenue drops - TradingView
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results - The Manila Times
[10-Q] Perspective Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Perspective Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Perspective Therapeutics (NYSE: CATX) posts Q1 loss, cash runway to late 2027 - Stock Titan
Perspective Therapeutics: $271M cash to advance 3 cancer trials - Stock Titan
Number of shareholders of Perspective Therapeutics, Inc. – AMEX:CATX - TradingView
Perspective Therapeutics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Transcript : Perspective Therapeutics, Inc.Shareholder/Analyst Call - marketscreener.com
MSN Money - MSN
JonesTrading Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $18 - Moomoo
RBC Capital Reaffirms Their Buy Rating on Perspective Therapeutics (CATX) - The Globe and Mail
Perspective Therapeutics (CATX) Receives a Buy from Piper Sandler - The Globe and Mail
RBC Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $14 - 富途牛牛
Wedbush Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Perspective Therapeutics Advances 212Pb Radioligand Therapy for Targeted Oncology with Regional Manufacturing and Theranostic Approach 1245 - Minichart
Perspective Therapeutics, Inc. (CATX) Shareholder/Analyst CallSlideshow (NYSE:CATX) 2026-05-04 - Seeking Alpha
Perspective Therapeutics (CATX) unveils 212Pb theranostic pipeline and manufacturing strategy - Stock Titan
Perspective Therapeutics: Decent Prospect In Radiopharmaceuticals Field - Seeking Alpha
BlackRock stake in Perspective Therapeutics (CATX): 5.25M shares - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: Tarsus Pharmaceuticals (TARS), Perspective Therapeutics (CATX) - The Globe and Mail
Perspective Therapeutics to Provide Several Upcoming Corporate Updates - The Manila Times
Perspective Therapeutics, Inc. to Provide Corporate Updates and Financial Results in May 2026 - Quiver Quantitative
Perspective Therapeutics maps out May updates, Q1 results on May 11 - Stock Titan
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Perspective Therapeutics (CATX) and UnitedHealth (UNH) - The Globe and Mail
CATX (Perspective Therapeutics Inc.) slips 1.41% after reporting Q4 2025 EPS that misses analyst estimates by 40.3%.Stock Community Signals - Cổng thông tin điện tử tỉnh Tây Ninh
CATX Technical Analysis | Trend, Signals & Chart Patterns | PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX) - ChartMill
Analysts’ Top Healthcare Picks: Perspective Therapeutics (CATX), Nektar Therapeutics (NKTR) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Immatics (IMTX), Incyte (INCY) and Perspective Therapeutics (CATX) - The Globe and Mail
Perspective Therapeutics reports interim trial results for NET therapy By Investing.com - Investing.com India
Pheochromocytoma and Paraganglioma Market to Exhibit Growth at 7.3% CAGR by 2036 Driven by the Advent of Drug Classes Such as SSTR2 analogs, Dopamine Receptor D2 Agonists, TAAs or TSAs, and Others | DelveInsight - GlobeNewswire Inc.
CATX Reiterates by Wedbush -- Price Target Maintained at $11 - GuruFocus
Perspective Therapeutics (NYSEAMERICAN:CATX) Shares Gap UpShould You Buy? - MarketBeat
[212Pb]VMT-α-NET Shows Promising Safety and Efficacy in Advanced Neuroendocrine Tumor Phase I/IIa Trial (Data Cutoff March 2026) - Minichart
Perspective Therapeutics (CATX) Updates Clinical Trial Results f - GuruFocus
Wedbush Reaffirms Outperform Rating for Perspective Therapeutics (NYSEAMERICAN:CATX) - MarketBeat
Perspective Therapeutics reports interim trial results for NET therapy - Investing.com
Perspective Therapeutics Provides Updated Interim Results From Phase 1/2a Cancer Trial - marketscreener.com
Perspective Therapeutics Highlights Encouraging Interim Neuroendocrine Tumor Data - TipRanks
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting - The Manila Times
Perspective Therapeutics posts updated Phase 1/2a [212Pb]VMT-α-NET data showing 43% response in Cohort 2 - TradingView
[8-K] Perspective Therapeutics, Inc. Reports Material Event - Stock Titan
EBITDA per share of Perspective Therapeutics, Inc. – FWB:AAJ0 - TradingView
Perspective Therapeutics (NASDAQ: CATX) sets 2026 director, auditor and pay vote - Stock Titan
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Sees Large Increase in Short Interest - MarketBeat
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Finanzdaten der Perspective Therapeutics Inc-Aktie (CATX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.34%
Kapitalisierung:
|
Volumen (24h):